FUNDAMENTALS · Fundamentals · CN Healthcare

Qyuns Therapeutics (2509) Fundamentals 2026 — P/E 9.9x, Revenue Analysis | SniperIQ

Qyuns Therapeutics (2509) is a CN-listed Healthcare company in Biotechnology with a market capitalization of HK

.6B, trading at HK
5.93 on the HKSE. This SniperIQ fundamentals page covers Qyuns Therapeutics's valuation (P/E 9.9x, P/B 4.5x), profitability (net margin 39.0%), revenue (¥786M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market CapHK
.6B
P/E (TTM)9.9x
Net Margin39.0%
Revenue (FY25)¥786M

Full research coverage

Frequently Asked Questions

What is Qyuns Therapeutics's market cap?

Qyuns Therapeutics (2509) has a market capitalization of approximately HK

.6B, trading at HK
5.93 on the HKSE. Market cap moves with the live share price.

What is Qyuns Therapeutics's P/E ratio?

Qyuns Therapeutics's trailing twelve-month P/E ratio is 9.9x, with a price-to-book (P/B) of 4.5x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Qyuns Therapeutics?

Qyuns Therapeutics runs a net profit margin of 39.0%, a gross margin of 88.5%, and an operating margin of 40.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Qyuns Therapeutics generate?

Qyuns Therapeutics reported revenue of ¥786M for fiscal year 2025, with net income of ¥306M and earnings per share (EPS) of 1.37. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Qyuns Therapeutics pay a dividend?

Qyuns Therapeutics does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Qyuns Therapeutics financially healthy?

Qyuns Therapeutics carries a debt-to-equity ratio of 0.84x and a current ratio of 2.22x, with a market beta of 1.47. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Qyuns Therapeutics a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Qyuns Therapeutics (2509) the key facts are: market cap HK

.6B, P/E 9.9x, revenue ¥786M, 52-week range 13.21-36.5. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Qyuns Therapeutics's full fundamentals live

Get Qyuns Therapeutics's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.